{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(1)"],"submitter":["de la Rocha C"],"pubmed_abstract":["Background
Despite the development and application of vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) around the world, the scientific community is still trying to find some therapies to avoid or ameliorate the fatal evolution of the Coronavirus disease 2019 (COVID-19). Since the publication of the potential use of ivermectin as a treatment against the disease, a pleiad of information about it has been published. However, the evidence is not strong or weak enough to conclude its usefulness in the clinical evolution of patients infected with SARS-CoV-2. We evaluate the efficacy and safety of ivermectin in the treatment of Mexican patients with asymptomatic and mild COVID-19 in a three-day administration in comparison to placebo.Methods
A randomi"],"journal":["BMC infectious diseases"],"pagination":["917"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9730611"],"repository":["biostudies-literature"],"pubmed_title":["Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial."],"pmcid":["PMC9730611"],"pubmed_authors":["de la Rocha C","Robles-Bojorquez JG","Mercado-Sesma AR","Vargas-Iniguez B","Valderrabano-Roldan CG","Tavares-Valdez A","Gomez-Mendez SC","Gutierrez-Dieck GA","Rosales-Galvan D","Luna-Gudino N","Milenkovic J","Mendez-Del Villar M","Hernandez-Puente CV","Iglesias-Palomares C","Venegas-Lopez BI","Cid-Lopez MA","Sanchez-Ortiz A","Mercado-Cerda J","Llamas-Velazquez RA","Perez-Rios AM","Meza-Acuna AI"],"additional_accession":[]},"is_claimable":false,"name":"Ivermectin compared with placebo in the clinical course in Mexican patients with asymptomatic and mild COVID-19: a randomized clinical trial.","description":"Background
Despite the development and application of vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) around the world, the scientific community is still trying to find some therapies to avoid or ameliorate the fatal evolution of the Coronavirus disease 2019 (COVID-19). Since the publication of the potential use of ivermectin as a treatment against the disease, a pleiad of information about it has been published. However, the evidence is not strong or weak enough to conclude its usefulness in the clinical evolution of patients infected with SARS-CoV-2. We evaluate the efficacy and safety of ivermectin in the treatment of Mexican patients with asymptomatic and mild COVID-19 in a three-day administration in comparison to placebo.Methods
A randomi","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-07-14T15:22:44.395Z","creation":"2024-11-08T13:29:02.531Z"},"accession":"S-EPMC9730611","cross_references":{"pubmed":["36482326"],"doi":["10.1186/s12879-022-07890-6"]}}